In vitro activity of new tetracycline analogs omadacycline and eravacycline against drug-resistant clinical isolates of mycobacterium abscessus

Amit Kaushik, Nicole Ammerman, Olumide Martins, Nicole M Parrish, Eric Nuermberger

Research output: Contribution to journalArticle

Abstract

Tigecycline is used in multidrug regimens for salvage therapy of Mycobacterium abscessus infections but is often poorly tolerated and has no oral formulation. Here, we report similar in vitro activity of two newly approved tetracycline analogs, omadacycline and eravacycline, against 28 drug-resistant clinical isolates of M. abscessus complex. Since omadacycline and eravacycline appear to be better tolerated than tigecycline and since omadacycline is also formulated for oral dosing, these tetracycline analogs may represent new treatment options for M. abscessus infections.

Original languageEnglish (US)
Article numbere00470-19
JournalAntimicrobial agents and chemotherapy
Volume63
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Mycobacterium
Tetracycline
Pharmaceutical Preparations
Salvage Therapy
Mycobacterium Infections
Infection
In Vitro Techniques
omadacycline
7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline
tigecycline
Therapeutics

Keywords

  • Drug susceptibility assay
  • Eravacycline
  • Mycobacterium abscessus
  • Omadacycline
  • Tetracyclines
  • Tigecycline

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

@article{b2aa724039634a01a9cfb724f9924b59,
title = "In vitro activity of new tetracycline analogs omadacycline and eravacycline against drug-resistant clinical isolates of mycobacterium abscessus",
abstract = "Tigecycline is used in multidrug regimens for salvage therapy of Mycobacterium abscessus infections but is often poorly tolerated and has no oral formulation. Here, we report similar in vitro activity of two newly approved tetracycline analogs, omadacycline and eravacycline, against 28 drug-resistant clinical isolates of M. abscessus complex. Since omadacycline and eravacycline appear to be better tolerated than tigecycline and since omadacycline is also formulated for oral dosing, these tetracycline analogs may represent new treatment options for M. abscessus infections.",
keywords = "Drug susceptibility assay, Eravacycline, Mycobacterium abscessus, Omadacycline, Tetracyclines, Tigecycline",
author = "Amit Kaushik and Nicole Ammerman and Olumide Martins and Parrish, {Nicole M} and Eric Nuermberger",
year = "2019",
month = "6",
day = "1",
doi = "10.1128/AAC.00470-19",
language = "English (US)",
volume = "63",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - In vitro activity of new tetracycline analogs omadacycline and eravacycline against drug-resistant clinical isolates of mycobacterium abscessus

AU - Kaushik, Amit

AU - Ammerman, Nicole

AU - Martins, Olumide

AU - Parrish, Nicole M

AU - Nuermberger, Eric

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Tigecycline is used in multidrug regimens for salvage therapy of Mycobacterium abscessus infections but is often poorly tolerated and has no oral formulation. Here, we report similar in vitro activity of two newly approved tetracycline analogs, omadacycline and eravacycline, against 28 drug-resistant clinical isolates of M. abscessus complex. Since omadacycline and eravacycline appear to be better tolerated than tigecycline and since omadacycline is also formulated for oral dosing, these tetracycline analogs may represent new treatment options for M. abscessus infections.

AB - Tigecycline is used in multidrug regimens for salvage therapy of Mycobacterium abscessus infections but is often poorly tolerated and has no oral formulation. Here, we report similar in vitro activity of two newly approved tetracycline analogs, omadacycline and eravacycline, against 28 drug-resistant clinical isolates of M. abscessus complex. Since omadacycline and eravacycline appear to be better tolerated than tigecycline and since omadacycline is also formulated for oral dosing, these tetracycline analogs may represent new treatment options for M. abscessus infections.

KW - Drug susceptibility assay

KW - Eravacycline

KW - Mycobacterium abscessus

KW - Omadacycline

KW - Tetracyclines

KW - Tigecycline

UR - http://www.scopus.com/inward/record.url?scp=85066436391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066436391&partnerID=8YFLogxK

U2 - 10.1128/AAC.00470-19

DO - 10.1128/AAC.00470-19

M3 - Article

VL - 63

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 6

M1 - e00470-19

ER -